Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas

Cancer

Volumn 78, Issue 5, 1996, Pages 1107-1113

  Kros, Johan M ^a   Hop, Wim C J ^a   Godschalk, Josiane J C J ^a   Krishnadath, Kausilia K ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

brain; cell proliferation; clinical outcome; glioma; grading; Ki 67; neoplasm; oligodendroglioma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0029818185     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5     Document Type: Article

References (42)

1. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer 1983;52:2107-14.
2. Burger PC, Rawlings CE, Cox EB. Clinicopathological correlations in the oligodendroglioma. Cancer 1987;59:1345-52.
3. Mørk SJ, Halvorsen TB, Lindegaard K-F, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986;45(1):65-78.
4. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 1992;76:428-34.
5. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
6. Gerdes J. An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer 1985;35:169-71.
7. Verhuyen R, Kuypers HJH, van Driel R. Ki67 detects a nuclear matrix-associated proliferation-related antigen. II. Localisation in mitotic cells and associated with chromosomes. J Cell Sci 1989;92:531-41.
8. Patsouris E, Stocker U, Kallmeyer V, Keiditsch E, Mehraein P, Stavrou D. Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors. Anticancer Res 1988;8:537-44.
9. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989; 115:179-88.
10. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 1991;81:675-9.
11. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Dodge RK, Kerns B-J, Burger PC. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 1994;34:674-9.
12. Key G, Becker MHG, Duchrow M, Schluter C, Gerdes J. New Ki-67 equivalent murine monoclonal antibodies (MIB-1-3) prepared against recombinant parts of the Ki-67 antigen. Anal Cell Pathol 1992;4:181.
13. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. The labelling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to the DNA. Exp Cell Res 1994;210:145-53.
14. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
15. Shi S, Key M, Kalra K. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-48.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187-220.
17. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-18.
18. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferation cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995;76:1809-13.
19. Montironi R, Collan Y, Scarpelli M, Sisti S, Barbatelli G, Carnevali A, et al. Reproducibility of mitotic counts and identification of mitotic figures in malignant glial tumors. Appl Pathol 1988;6:258-65.
20. Johnson HA, Haymaker WE, Rubini JR, Fliedner TM, Bond VP, Cronkite EP, et al. A radioautographic study of a human brain and glioblastoma multiforme after the in vivo uptake of tritiated thymidine. Cancer 1960;13:636-42.
21. Germano IM, Ito M, Cho KG, Hoshino T, Davis RL, Wilson CB. Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg 1989;70:701-6.
22. Hoshino T, Nagashima T, Cho KG, Davis RL, Donegan J, Slusarz M, et al. Variability in the proliferative potential of human gliomas. J Neurooncol 1989;7:137-43.
23. Detta A, Hitchcock E. Rapid estimation of the proliferating index of brain tumours. J Neurooncol 1990;8:245-53.
24. Dinda AK, Kharbanda K, Sarkar C, Roy S, Mathur M, Banerji AK. In-vivo proliferative potential of primary human brain tumors; its correlation with histological classification and morphological features: I gliomas. Pathology 1993;25:4-9.
25. Hall PA, Levison DA. Review: Assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184-92.
26. Gelb AB, Kamel OW, LeBrun DP, Warnke RA. Estimation of tumor growth fractions in archival formalin-fixed, paraffin-embedded tissues using two anti-PCNA/cyclin monoclonal antibodies. Factors affecting reactivity. Am J Pathol 1992; 141(6):1453-8.
27. Khoshyomn S, Maier H, Morimura T, Kitz K, Budka H. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 1993; 86(6):582-9.
28. Karamitopoulou E, Perentes E, Melachrinou M, Maraziotis T. Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol 1993;85:316-22.
29. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986;10:611-7.
30. Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol 1987;73:361-4.
31. Dierendonck JH van, Keyezer R, van de Velde CJH, Cornelisse CJ. Nuclear distribution of the Ki67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 1989;49:2999-3006.
32. Schröder R, Bien K, Kott R, Meyers I, Vossing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol 1991;82:389-94.
33. Morimura T, Budka H. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S-phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67. Acta Neuropathol 1989;77:276-82.
34. Raghavan R, Steart PV, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol 1990;16:123-33.
35. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
36. Bailey P, Cushing H. A classification of the tumors of the glioma group on a histogenesis basis, with a correlated study of prognosis. Philadelphia: J.B. Lippincott Co., 1929.
37. Earnest F III, Kernohan JW, Craig WM. Oligodendrogliomas. A review of two hundred cases. Arch Neurol Psychiatry 1950;63:964-76.
38. Reymond A, Ringertz N. L'oligodendrogliome. Etude anatomo-clinique de 74 cas. Schweiz Arch Neurochir Neurol Psychiatr 1950;65:221-254.
39. Horrax G, Wu WQ. Postoperative survival of patients with intracranial oligodendroglioma with special reference to radical tumor removal. J Neurosurg 1951;8:473-9.
40. Roberts M, German WJ. A long term study of patients with oligodendrogliomas. Follow-up of 50 cases, including Dr. Harvey Cushing's series. J Neurosurg 1966;24:697-700.
41. Rousta B. Etude anatomo-clinique de 22 cas d'oligodendrogliomes. Rev Med Suisse Romande 1972;92(6):393-418.
42. Kros JM, van Eden CG, Vissers CJ, Mulder AH, van der Kwast ThH. Prognostic relevance of DNA flow cytometry in the oligodendroglioma. Cancer 1992;69(7):74-81.